- Home
- NATR vs BDSX Comparison
NATR vs BDSX Comparison
Compare NATR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATR
- BDSX
- Stock Information
- Founded
- NATR 1972
- BDSX 2005
- Country
- NATR United States
- BDSX United States
- Employees
- NATR N/A
- BDSX N/A
- Industry
- NATR Biotechnology: Pharmaceutical Preparations
- BDSX Precision Instruments
- Sector
- NATR Health Care
- BDSX Health Care
- Exchange
- NATR Nasdaq
- BDSX Nasdaq
- Market Cap
- NATR N/A
- BDSX 194.9M
- IPO Year
- NATR N/A
- BDSX 2020
- Fundamental
- Price
- NATR $15.00
- BDSX $1.51
- Analyst Decision
- NATR Strong Buy
- BDSX Strong Buy
- Analyst Count
- NATR 2
- BDSX 4
- Target Price
- NATR $19.50
- BDSX $3.08
- AVG Volume (30 Days)
- NATR 42.4K
- BDSX 308.8K
- Earning Date
- NATR 11-07-2024
- BDSX 11-01-2024
- Dividend Yield
- NATR N/A
- BDSX N/A
- EPS Growth
- NATR 114.95
- BDSX N/A
- EPS
- NATR 0.88
- BDSX N/A
- Revenue
- NATR $445,095,000.00
- BDSX $65,562,000.00
- Revenue This Year
- NATR $2.07
- BDSX $46.97
- Revenue Next Year
- NATR $2.62
- BDSX $30.43
- P/E Ratio
- NATR $17.44
- BDSX N/A
- Revenue Growth
- NATR 1.36
- BDSX 48.92
- 52 Week Low
- NATR $10.81
- BDSX $1.11
- 52 Week High
- NATR $21.72
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- NATR 42.45
- BDSX 48.94
- Support Level
- NATR $14.90
- BDSX $1.24
- Resistance Level
- NATR $15.88
- BDSX $1.43
- Average True Range (ATR)
- NATR 0.62
- BDSX 0.10
- MACD
- NATR -0.21
- BDSX 0.01
- Stochastic Oscillator
- NATR 5.24
- BDSX 64.44
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.